Natixis Advisors LLC Has $783,000 Stock Holdings in Stevanato Group S.p.A. (NYSE:STVN)

Natixis Advisors LLC increased its position in shares of Stevanato Group S.p.A. (NYSE:STVN) by 27.3% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 42,674 shares of the company’s stock after purchasing an additional 9,146 shares during the quarter. Natixis Advisors LLC’s holdings in Stevanato Group were worth $783,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in STVN. Hilltop National Bank raised its position in Stevanato Group by 34.3% in the 2nd quarter. Hilltop National Bank now owns 4,395 shares of the company’s stock valued at $81,000 after purchasing an additional 1,122 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Stevanato Group by 54.2% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,089 shares of the company’s stock valued at $84,000 after buying an additional 1,086 shares during the last quarter. Harbor Capital Advisors Inc. lifted its position in Stevanato Group by 109.1% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 8,867 shares of the company’s stock worth $163,000 after buying an additional 4,626 shares in the last quarter. Raymond James Trust N.A. grew its holdings in Stevanato Group by 18.7% during the 2nd quarter. Raymond James Trust N.A. now owns 10,239 shares of the company’s stock worth $188,000 after acquiring an additional 1,613 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. acquired a new stake in Stevanato Group in the 1st quarter valued at about $241,000.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on STVN shares. Citigroup reduced their target price on shares of Stevanato Group from $30.00 to $28.00 and set a “buy” rating on the stock in a research report on Wednesday, August 7th. Morgan Stanley reduced their price objective on Stevanato Group from $26.00 to $22.00 and set an “equal weight” rating on the stock in a report on Monday, July 15th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of €30.60 ($33.63).

Stevanato Group Stock Down 4.5 %

Shares of NYSE STVN opened at €19.30 ($21.21) on Friday. Stevanato Group S.p.A. has a 1 year low of €16.56 ($18.20) and a 1 year high of €35.56 ($39.08). The firm’s 50-day moving average is €20.34 and its 200-day moving average is €23.35. The company has a current ratio of 1.74, a quick ratio of 1.13 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $5.70 billion, a PE ratio of 35.09, a price-to-earnings-growth ratio of 6.06 and a beta of 0.59.

Stevanato Group (NYSE:STVN) last released its earnings results on Tuesday, August 6th. The company reported €0.09 ($0.10) EPS for the quarter, missing analysts’ consensus estimates of €0.10 ($0.11) by (€0.01) (($0.01)). The business had revenue of €259.60 million for the quarter, compared to analyst estimates of €254.92 million. Stevanato Group had a return on equity of 10.89% and a net margin of 11.27%. Stevanato Group’s revenue was up 1.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.15 EPS. Equities analysts expect that Stevanato Group S.p.A. will post 0.51 EPS for the current year.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.